Accès ouvert déclaré
2022
article
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
Atsushi Tanaka, Masataka Sata, Yosuke Okada, Hiroki Teragawa, Michio Shimabukuro, Isao Taguchi, Kazuo Matsunaga, Yumiko Kanzaki, Hisako Yoshida, Tomoko Ishizu, Shinichiro Ueda, Masafumi Kitakaze, Toyoaki Murohara, Koichi Node, Yoshihiko Nishio, Teruo Inoue, Mitsuru Ohishi, Kazuomi Kario, Wataru Shimizu, Hideaki Jinnouchi, Hirofumi Tomiyama, Koji Maemura, Makoto Suzuki, Shin‐ichi Ando, Haruo Kamiya, Tomohiro Sakamoto, Mamoru Nanasato, Munehide Matsuhisa, Junya Ako, Yoshimasa Aso, Masaharu Ishihara, Kazuo Kitagawa, Akira Yamashina, Yumi Ikehara, Ayako Takamori, Miki Mori, Kaori Yamaguchi, Machiko Asaka, Tetsuya Kaneko, Masashi Sakuma, Shigeru Toyoda, Takahisa Nasuno, Michiya Kageyama, Toshie Iijima, Haruka Kishi, Hirotsugu Yamada, Kenya Kusunose, Daiju Fukuda, Shusuke Yagi, Koji Yamaguchi, Takayuki Ise, Yutaka Kawabata, Akio Kuroda, Yuichi Akasaki, Mihoko Kurano, Satoshi Hoshide, Takahiro Komori, Tomoyuki Kabutoya, Yukiyo Ogata, Yuji Koide, Hiroaki Kawano, Satoshi Ikeda, Satoki Fukae, Seiji Koga, Yukihito Higashi, Shinji Kishimoto, Masato Kajikawa, Tatsuya Maruhashi, Yoshiaki Kubota, Yoshisato Shibata, Nehiro Kuriyama, Ikuko Nakamura, Kanemitsu Hironori, Bonpei Takase, Yuichi Orita, Chikage Oshita, Yuko Uchimura, Ruka Yoshida, Yukihiko Yoshida, Hirohiko Suzuki, Yasuhiro Ogura, Mayuho Maeda, Masaki Takenaka, Takumi Hayashi, Mirai Hirose, Itaru Hisauchi, Toshiaki Kadokami, Ryô Nakamura, Junji Kanda, Masaaki Hoshiga, Koichi Sohmiya, Arihiro Koyosue, Hiroki Uehara, Naoto Miyagi, Toshiya Chinen, Kentaro Nakamura, Chikashi Nago, Suguru Chiba, Sho Hatano, Yoshikatsu Gima, Masami Abe, Masayoshi Ajioka, Hiroshi Asano, Yoshihiro Nakashima, Hiroyuki Osanai, Takahiro Kanbara, Yusuke Sakamoto, Mitsutoshi Oguri, Shiou Ohguchi, Kunihiko Takahara, Kazuhiro Izumi, Kenichiro Yasuda, Akihiro Kudo, Noritaka Machii, Ryota Morimoto, Yoshiyuki Bando, Takahiro Okumura, Toru Kondo, Shin‐ichiro Miura, Yuhei Shiga, Joji Mirii, Makoto Sugihara, Tadaaki Arimura, Junko Nakano, Kazuhisa Kodama, Nobuyuki Ohte, Tomonori Sugiura, Kazuaki Wakami, Yasuhiko Takemoto, Minoru Yoshiyama, Taichi Shuto, Kazuo Fukumoto, Kenichi Tanaka, Satomi Sonoda, Akemi Tokutsu, Takashi Otsuka, Fumi Uemura, Kenji Koikawa, Megumi Miyazaki, Maiko Umikawa, Manabu Narisawa, Machi Furuta, Hiroshi Minami, M. Doi, Kazuhiro Sugimoto, Susumu Suzuki, Akira Kurozumi, Kosuke Nishio
36Citations signalées, ce qui n’est pas une note de qualité
13Institutions déclarées
1Pays d’affiliation déclarés
Rattachement africain : jp.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIMS: To examine the effects of a 24-month treatment with ipragliflozin on carotid intima-media thickness (IMT) in type 2 diabetes patients. METHODS AND RESULTS: In this multicenter, prospective, randomized, open-label, and blinded-endpoint investigator-initiated clinical trial, adults with type 2 diabetes and haemoglobin A1C (HbA1c) of 6.0-10.0% (42-86 mmol/mol) were randomized equally to ipragliflozin (50 mg daily) and non-sodium-glucose cotransporter-2 (SGLT2) inhibitor use of standard-care (control group) for type 2 diabetes and were followed-up to 24 months. The primary endpoint was the change in mean common carotid artery IMT (CCA-IMT) from baseline to 24 months. A total of 482 patients were equally allocated to the ipragliflozin (N = 241) and control (N = 241) groups, and 464 patients (median age 68 years, female 31.7%, median type 2 diabetes duration 8 years, median HbA1c 7.3%) were included in the analyses. For the primary endpoint, the changes in the mean CCA-IMT from baseline to 24 months were 0.0013 [95% confidence interval (CI), -0.0155-0.0182] mm and 0.0015 (95% CI, -0.0155-0.0184) mm in the ipragliflozin and control groups, respectively, with an estimated group difference (ipragliflozin-control) of -0.0001 mm (95% CI, -0.0191-0.0189; P = 0.989). A group difference in HbA1c change at 24 months was also non-significant between the treatment groups [-0.1% (95% CI, -0.2-0.1); P = 0.359]. CONCLUSION: Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
- Date Crossref
- 29/10/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Disease Prevention